Previous 10 | Next 10 |
Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products and provision of boutique CDMO (“CDMO”) services, has entered a d...
2023-12-29 09:30:29 ET More on Scinai Immunotherapeutics Scinai Immunotherapeutics regains compliance with stockholders' equity rule Seeking Alpha’s Quant Rating on Scinai Immunotherapeutics Historical earnings data for Scinai Immunotherapeutics Financ...
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds PR Newswire JERUSALEM , Dec. 29, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused both on developme...
Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of both inflammation and immunology. During the webinar, SCNI CEO Amir Reichman will present an overview of the company’s performance throughout the year 2023, along with a discussio...
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9 PR Newswire JERUSALEM , Dec. 27, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunolo...
A recent paper that was published in the “Nature" journal has redefined rheumatoid arthritis (RA) and potentially opened the door to the development of targeted therapies. Researchers analyzed tissue collected from the synovial joints of almost 80 people diagnosed with moder...
Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, has announced successful preclinical trial results of its innovative anti ...
Scinai Announces Promising Results in a Psoriatic Human Skin Model PR Newswire JERUSALEM , Dec. 12, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology biologica...
Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, is announcing the publication of a peer-reviewed article regarding NanoAbs. Th...
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug PR Newswire Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases...
News, Short Squeeze, Breakout and More Instantly...
Scanner Technologies Corp Company Name:
SCNI Stock Symbol:
OTCMKTS Market:
Scanner Technologies Corp Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 0.6% to $128.44 on volume of 203,267,889 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 22.1% to $0.5152 on volume of 200,531,827 shares PROSHARES TRUST (SQQQ) fell 0.7% to $7.46 on volume o...
2024-07-15 12:31:08 ET Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis. The biotechnology firm’s shares experienced a significa...